- AstraZeneca said Japanese regulators had approved its supplementary oral treatment for type-one diabetic patients, whose glucose levels were not adequately controlled with insulin alone.

The approval was based on data from the Phase III DEPICT clinical programme diabetes treatment Forxiga which, when given as an oral treatment in addition to adjustable insulin in patients with inadequately-controlled type-1 diabetes, demonstrated 'significant and clinically-meaningful reductions from baseline in average blood glucose levels HbA1c (primary endpoint), weight and total daily insulin dose (secondary endpoints) at 24 weeks, at both 5mg and 10mg doses,' the company said.

'This approval of Forxiga in Japan means that people with type-1 diabetes whose glucose levels are not adequately controlled with insulin alone now have a new oral treatment option available to them. Forxiga will help address a significant unmet need in this patient population, and this approval in type-1 diabetes builds on the well-established clinical profile of Forxiga,' said Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals.

Story provided by